These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26412798)

  • 1. Risk factors for the development of donor-specific antibodies after pediatric heart transplantation.
    Godown J; Slaughter JC; Fossey SC; McKane M; Dodd DA
    Pediatr Transplant; 2015 Dec; 19(8):906-10. PubMed ID: 26412798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preformed and de novo DSA are associated with T-cell-mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy.
    Schluckebier D; Cousin VL; Petit LM; Belli D; Wildhaber B; Rougemont AL; Villard J; Ferrari-Lacraz S; McLin VA
    Pediatr Transplant; 2020 Feb; 24(1):e13611. PubMed ID: 31682057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
    Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
    Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-specific anti-HLA antibodies in pediatric renal transplant recipients with creeping creatinine: Prevalence, histological correlations, and impact on patient and graft survival.
    Monteverde ML; Chaparro A; Goldberg J; Marcos CY; Padros K; Balbarrey Z; Briones L; Rush D
    Pediatr Transplant; 2015 Nov; 19(7):684-90. PubMed ID: 26212912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation.
    Irving CA; Carter V; Gennery AR; Parry G; Griselli M; Hasan A; Kirk CR
    J Heart Lung Transplant; 2015 Oct; 34(10):1310-7. PubMed ID: 26123951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement (C1q) Binding De Novo Donor-Specific Antibodies and Cardiac-Allograft Vasculopathy in Pediatric Heart Transplant Recipients.
    Das BB; Lacelle C; Zhang S; Gao A; Fixler D
    Transplantation; 2018 Mar; 102(3):502-509. PubMed ID: 28885488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of flow PRA on outcome in pediatric heart recipients in modern era: An analysis of the Pediatric Heart Transplant Study database.
    Das BB; Pruitt E; Molina K; Ravekes W; Auerbach S; Savage A; Knox L; Kirklin JK; Naftel DC; Hsu D;
    Pediatr Transplant; 2018 Feb; 22(1):. PubMed ID: 29144053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation.
    Grabhorn E; Binder TM; Obrecht D; Brinkert F; Lehnhardt A; Herden U; Peine S; Nashan B; Ganschow R; Briem-Richter A
    Transplantation; 2015 Sep; 99(9):1876-81. PubMed ID: 25706279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
    Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Monitoring of Donor-specific Anti-HLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo Antibodies.
    Kubal C; Mangus R; Saxena R; Lobashevsky A; Higgins N; Fridell J; Tector AJ
    Transplantation; 2015 Aug; 99(8):e49-56. PubMed ID: 25769071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor-specific HLA antibodies in paediatric cardiac transplant recipients are associated with poor graft survival.
    Irving C; Carter V; Parry G; Hasan A; Kirk R
    Pediatr Transplant; 2011 Mar; 15(2):193-7. PubMed ID: 21199210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
    Cooper JE; Gralla J; Chan L; Wiseman AC
    Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of anti-HLA antibodies associated with ventricular assist device use in pediatric patients: A United Network for Organ Sharing database analysis.
    Magdo HS; Schumacher KR; Yu S; Gajarski RJ; Friedland-Little JM
    Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28568969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss.
    Fidler S; Swaminathan R; Lim W; Ferrari P; Witt C; Christiansen FT; D'Orsogna LJ; Irish AB
    Transpl Immunol; 2013 Dec; 29(1-4):22-7. PubMed ID: 24090807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor-specific antibodies are associated with micro- and macrovascular coronary disease, restrictive myocardial damage, and poor outcome in heart-transplanted patients.
    Clemmensen TS; Koefoed-Nielsen P; Jensen LA; Poulsen SH; Holm NR; Løgstrup BB; Christiansen EH; Dijkstra J; Valen KPB; Eiskjaer H
    Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28627046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial differences in the development of de-novo donor-specific antibodies and treated antibody-mediated rejection after heart transplantation.
    Cole RT; Gandhi J; Bray RA; Gebel HM; Yin M; Shekiladze N; Young A; Grant A; Mahoney I; Laskar SR; Gupta D; Bhatt K; Book W; Smith A; Nguyen D; Vega JD; Morris AA
    J Heart Lung Transplant; 2018 Apr; 37(4):503-512. PubMed ID: 29198929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.